Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: Novel preliminary evidence

Histopathology

Volumn 58, Issue 7, 2011, Pages 1148-1156

  Marioni, Gino ^a   Staffieri, Alberto ^a   Giacomelli, Luciano ^b   Lionello, Marco ^a   Guzzardo, Vincenza ^b   Busnardo, Alessandra ^a   Blandamura, Stella ^b  

^a Otolaryngology Section   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Laryngeal carcinoma; Mammalian target of rapamycin; Marker; Prognosis; Targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARYNGECTOMY; LARYNX CARCINOMA; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ITALY; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

MAMMALIA;

EID: 79959743207     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03864.x     Document Type: Article

References (26)

1. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutical target against cancer. Cancer Biol. Ther. 2003; 2; S169-S177.
2. Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol. Ther. 2006; 5; 1065-1073.
3. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009; 115(Suppl. 10); 2313-2320.
4. Yu G, Wang J, Chen Y et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin. Cancer Res. 2009; 15; 1821-1829.
5. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008; 11; 63-76.
6. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 2004; 16; 564-575.
7. No JH, Jeon YT, Park IA et al. Expression of mTOR protein and its clinical significance in endometrial cancer. Med. Sci. Monit. 2009; 15; 301-305.
8. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev. 2006; 32; 504-515.
9. Greene FL, Page DL, Fleming ID et al. (eds) AJCC cancer staging manual, 6th edn. New York: Springer, 2002.
10. Pinsolle J, Pinsolle V, Majoufre C, Duroux S, Demeaux H, Siberchicot F. Prognostic value of histologic findings in neck dissections for squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1997; 123; 145-148.
11. Hoffman HT, Porter K, Karnell LH et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116(Suppl. 111); 1-13.
12. Amornphimoltham P, Patel V, Sodhi A et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005; 65; 9953-9961.
13. Liu FY, Zhao ZJ, Li P, Ding X, Zong ZH, Sun CF. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. Br. J. Oral Maxillofac. Surg. 2010; 48; 291-296.
14. Molinolo AA, Hewitt SM, Amornphimoltham P et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin. Cancer Res. 2007; 13; 4964-4973.
15. Nathan CA, Amirghahari N, Rong X et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007; 67; 2160-2168.
16. Krecicki T, Fraczek M, Jelen M, Zatonski T, Szkudlarek T, Dus D. Expression of c-myc oncoprotein in laryngeal squamous cell carcinoma. Acta Otolaryngol. 2004; 124; 634-637.
17. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135; 1322-1332.
18. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a metaanalysis. Clin. Cancer Res. 2005; 11; 1434-1440.
19. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009; 104; 1585-1589.
20. Calgaro N, Marioni G, Blandamura S et al. P27 and MIB-1 expression is related to malignancy recurrence in laryngeal carcinoma treated with partial laryngectomy: preliminary results. J. Otolaryngol. 2007; 36; 98-105.
21. Pruneri G, Pignataro L, Carboni N et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J. Clin. Oncol. 1999; 17; 3150-3159.
22. Liu M, Lawson G, Delos M et al. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur. Arch. Otorhinolaryngol. 2003; 260; 28-34.
23. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2009; 2; 45.
24. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. 2006; 5; 671-688.
25. Lei W, Jia T, Su Z, Wen W, Zhu X. Combined effect of rapamycin and cisplatin on survival of Hep-2 cells invitro. Oncol. Res. 2009; 18; 73-81.
26. Ekshyyan O, Mills GM, Lian T et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck. 2010; 32; 1619-1628.